Payment overview · 2025
General Payments
$58.21
2 reported records · 1 companies
Healthcare provider profile · identity verified
Anil Rathi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AUSTIN, TX · NPI 1215321492
Verified facts
What the public records show
CMS Open Payments records show Anil Rathi, M.D. received $58.21 in general payments during 2025 across 2 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 385 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.21 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $58.21 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $58.21 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $58.21 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 385 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
385 | 57 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 587 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 458 | 73 |
| Eliquis | Apixaban | 385 | 57 |
| Gabapentin | Gabapentin | 341 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 337 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 321 | 69 |
| Furosemide | Furosemide | 278 | 67 |
| Lisinopril | Lisinopril | 224 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 216 | 61 |
| Potassium Chloride | Potassium Chloride | 211 | 40 |
| Losartan Potassium | Losartan Potassium | 187 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 40 |
| Myrbetriq | Mirabegron | 155 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 40 |
| Donepezil Hcl | Donepezil Hcl | 146 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 145 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 32 |
| Metformin Hcl | Metformin Hcl | 142 | 34 |
| Trazodone Hcl | Trazodone Hcl | 134 | 37 |
| Carvedilol | Carvedilol | 125 | 38 |
| Sertraline Hcl | Sertraline Hcl | 123 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 118 | 32 |
| Famotidine | Famotidine | 112 | 26 |
| Mirtazapine | Mirtazapine | 112 | 28 |
| Levetiracetam | Levetiracetam | 106 | 21 |
| Tramadol Hcl | Tramadol Hcl | 102 | 33 |
| Allopurinol | Allopurinol | 96 | 15 |
| Memantine Hcl | Memantine Hcl | 95 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 22 |
| Spironolactone | Spironolactone | 87 | 19 |
| Simvastatin | Simvastatin | 86 | 15 |
| Lorazepam | Lorazepam | 84 | 28 |
| Divalproex Sodium | Divalproex Sodium | 81 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 18 |
| Montelukast Sodium | Montelukast Sodium | 78 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 76 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | suppressed |
| Omeprazole | Omeprazole | 72 | 23 |
| Baclofen | Baclofen | 69 | 15 |
| Methocarbamol | Methocarbamol | 65 | 18 |
| Pregabalin | Pregabalin | 64 | suppressed |
| Latanoprost | Latanoprost | 60 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 25 |
| Xarelto | Rivaroxaban | 58 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 57 | 11 |
| Nifedipine Er | Nifedipine | 57 | suppressed |
| Torsemide | Torsemide | 57 | 12 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Tradjenta | Linagliptin | 53 | suppressed |
| Prednisone | Prednisone | 51 | 21 |
| Glipizide | Glipizide | 50 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 49 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 46 |
| Cephalexin | Cephalexin | 45 | 23 |
| Alendronate Sodium | Alendronate Sodium | 44 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 43 | suppressed |
| Finasteride | Finasteride | 41 | suppressed |
| Risperidone | Risperidone | 41 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 30 |
| Hydrocortisone | Hydrocortisone | 36 | suppressed |
| Xifaxan | Rifaximin | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Alogliptin | Alogliptin Benzoate | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 20 |
| Prazosin Hcl | Prazosin Hcl | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Brilinta | Ticagrelor | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 15 |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | 19 |
| Alprazolam | Alprazolam | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | 14 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Scopolamine | Scopolamine | 22 | suppressed |
| Azathioprine | Azathioprine | 21 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Leflunomide | Leflunomide | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Rhopressa | Netarsudil Mesylate | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | 14 |
| Celecoxib | Celecoxib | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 13 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Rytary | Carbidopa/Levodopa | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Glucagon Emergency Kit | Glucagon | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | 11 |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Fanapt | Iloperidone | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Prezista | Darunavir | 12 | suppressed |
| Ritonavir | Ritonavir | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $58.21 · 2 records | PFIZER INC. | ELIQUIS, PAXLOVID | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error